Honda Atlas Cars (Pakistan) Limited

Analyst Briefing Takeaways

PSX: HCAR Bloomberg: HCAR: PA Reuters: HATC. PSX

HCAR: 1QMY23 Conference Call Key Takeaways

- Honda Atlas Cars held its corporate briefing today to discuss 1QMY23 financial results and future outlook. Earlier, the company reported an EPS of PKR 4.61 down 29% YoY. The lower EPS was due to gross margin contraction and higher other expense.
- As per the management, automobile industry is likely to witness 20%-30% decline in sales during FY23 due to increase in prices, higher interest rates and change in auto financing terms.
- The company has announced that it will be launching the CKD variant of HR-V in Pakistan, details of which will be announced in the coming months.
- Concerning the massive price increase of its products, the management has stated that only currency depreciation has been passed on to customers, while increases in raw material prices have been absorbed by the company, resulting in margins shrinkage.
- HCAR's current pricing has been done at a USD of PKR 235. The company has also stated that if the USD remains at the current level of 238 - 240, without a price increase, the company's margins will decline to 3.0%/3.5%.
- In terms of currency depreciation, the management apprised that PKR/USD depreciation accounts for 70% of the company's exchange exposure, while PKR/JPY contributes 10%.
- With respect to CKD kit imports, the management informed that SBP has provided a quota for the import of CKD kits, under which 50% of the average of last 4-month imports was allowed in July, with the quota percentage increasing to 60% in August and 70% in September.
- The company has observed only two non-production days (NPD) up till now, with no plans for future NPDs.
- According to the management, auto financing accounted for more than 40% of the company's sales prior to the SBP's regulation; however, currently it has decreased to 30%-35%.
- The company currently has no plans to export automobiles. However, it is considering exporting some auto parts to certain markets to see how they perform.
- The updated localization levels for City, Civic, and BR-V in terms of parts are 70%, 60%, and 50%, respectively.
- The management also stated that the super tax adjustment will be done in MY23.



Pakistan Research

| Key Data | |
|-------------------------|--------|
| PSX Ticker | HCAR |
| Target Price (PKR) | 173 |
| Current Price (PKR) | 160 |
| Upside/(Downside) (%) | +8% |
| Dividend Yield (%) | 4.4% |
| Total Return (%) | 12% |
| 12-month High (PKR) | 400 |
| 12-month Low (PKR) | 162 |
| Outstanding Shares (mn) | 142.80 |
| Market Cap (PKR mn) | 22,848 |
| Year End | March |
| | |

Source: Company Accounts, Akseer Research

Arshad Mansoor arshad.mansoor@alphacapital.com.pk



Valuation Basis

Our PT for Honda Atlas Cars (Pakistan) Limited (HCAR) has been computed using Free cash flow to equity (FCFE) method. We have used a risk free rate of 13.0%, beta of 1.0 & market risk premium of 6% to arrive at cost of equity of 19.0%.

Investment Thesis

We have a 'HOLD' recommendation on the stock based on our PT of 173/share. Our price taregt provides an upside of 8% along with a dividend yield of 4.4%. Our investment case on HCAR is based on (1) Reduction in sale volumes and, (2) steady gross profit margins.

Risks

Key risks to our investment thesis are1) higher than anticipated increase in raw material cost, 2) slowdown in demand 3) higher than expected PKR depreciation and 4) unfavorable government policies.

Company Description

Honda Atlas Cars (Pakistan) Limited engages in the assembly, manufacture, and sale of Honda vehicles and spare parts in Pakistan. It offers various models, including Honda Accord, Honda CR-V, Honda CR-Z, Honda Civic, and Honda City cars. The company was incorporated in 1992 and is headquartered in Lahore, Pakistan. Honda Atlas Cars (Pakistan) Limited is a subsidiary of Honda Motor Company Limited.

Financial Highlights - HCAR

| Income Statement (PKR mn) | | | | | | |
|---------------------------|--------|--------|---------|--------|---------|---------|
| | MY20A | MY21A | MY22A | MY23E | MY24F | MY25F |
| Net sales | 55,046 | 67,362 | 108,048 | 87,338 | 103,830 | 118,108 |
| Cost of sales | 50,955 | 63,586 | 102,470 | 83,010 | 98,425 | 111,280 |
| Gross Profit | 4,091 | 3,776 | 5,578 | 4,328 | 5,405 | 6,829 |
| SG & A | 1,407 | 1,561 | 2,207 | 1,991 | 2,098 | 2,213 |
| Operating Profit | 2,685 | 2,215 | 3,370 | 2,337 | 3,307 | 4,616 |
| Other income | 639 | 918 | 2,005 | 3,048 | 1,910 | 1,484 |
| Other charges | 1,049 | 237 | 984 | 1,185 | 1,086 | 976 |
| Finance cost | 727 | 116 | 116 | 180 | 207 | 197 |
| Profit before tax | 1,547 | 2,781 | 4,275 | 4,020 | 3,924 | 4,926 |
| Taxation | 865 | 987 | 1,765 | 1,809 | 1,295 | 1,626 |
| Profit after tax | 682 | 1,793 | 2,510 | 2,211 | 2,629 | 3,301 |

Source: Company Accounts, Akseer Research

| Balance sheet (PKR mn) | | | | | | |
|----------------------------|--------|--------|--------|--------|--------|--------|
| | MY20A | MY21A | MY22A | MY23E | MY24F | MY25F |
| PPE | 4,616 | 7,788 | 9,914 | 10,546 | 11,383 | 12,277 |
| Other LT assets | 624 | 417 | 1,033 | 1,195 | 1,384 | 1,636 |
| Non-Current Assets | 5,240 | 8,205 | 10,948 | 11,740 | 12,767 | 13,913 |
| Current assets | 26,602 | 36,950 | 59,315 | 50,040 | 54,699 | 57,911 |
| Total Assets | 31,842 | 45,155 | 70,263 | 61,780 | 67,466 | 71,824 |
| Non-Current liabilities | 474 | 3,053 | 4,317 | 3,897 | 3,750 | 3,645 |
| Current liabilities | 14,810 | 23,906 | 45,985 | 36,711 | 40,772 | 43,006 |
| Total Liabilities | 15,285 | 26,959 | 50,302 | 40,608 | 44,522 | 46,651 |
| Equity | 16,557 | 18,196 | 19,961 | 21,172 | 22,944 | 25,173 |
| Total Equity & liabilities | 31,842 | 45,155 | 70,263 | 61,780 | 67,466 | 71,824 |

Source: Company Accounts, Akseer Research

| Cashflow statement (PKR mn) | | | | | | |
|-----------------------------|---------|--------|---------|---------|---------|---------|
| | MY20A | MY21A | MY22A | MY23E | MY24F | MY25F |
| Net Income | 682 | 1,793 | 2,510 | 2,211 | 2,629 | 3,301 |
| Non-cash Charges | 827 | 704 | 1,040 | 1,391 | 1,503 | 1,620 |
| Operating Cash flows | (2,484) | 13,305 | 14,147 | 505 | 3,777 | 2,693 |
| FCFF | (866) | 9,497 | 4,817 | (2,010) | 998 | (317) |
| Net borrowings | 2,353 | 78 | 666 | (598) | (322) | (322) |
| FCFE | 1,166 | 9,500 | 5,415 | (2,707) | 538 | (771) |
| Net change in cash | 130 | 13,399 | (2,126) | (4,386) | (1,067) | (2,664) |
| Closing cash | 1,522 | 14,921 | 12,795 | 8,600 | 7,534 | 4,870 |

Source: Company Accounts, Akseer Research

Disclaimer

This report has been prepared and marketed jointly by Akseer Research (Pvt) Limited and Alpha Capital (Pvt) Limited, hereinafter referred jointly as "JV" and is provided for information purposes only. Under no circumstances this is to be used or considered as an offer to sell or solicitation of any offer to buy. While reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. From time to time, the JV and/or any of their officers or directors may, as permitted by applicable laws, have a position, or otherwise be interested in any transaction, in any securities directly or indirectly subject of this report. This report is provided only for the information of professionals who are expected to make their own investment decisions without undue reliance on this report. Investments in capital markets are subject to market risk and the JV accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. In particular, the report takes no account of the investment objectives, financial situation and particular needs of investors, who should seek further professional advice or rely upon their own judgment and acumen before making any investment. The views expressed in this report are those of the JV's Research Department and do not necessarily reflect those of the JV or its directors. Akseer Research and Alpha Capital as firms may have business relationships, including investment--banking relationships, with the companies referred to in this report. The JV or any of their officers, directors, principals, employees, associates, close relatives may act as a market maker in the securities of the companies mentioned in this report, may have a financial interest in the securities of these companies to an amount exceeding 1% of the value of the securities of these companies, may serve or may have served in the past as a director or officer of these companies, may have received compensation from these companies for corporate advisory services, brokerage services or underwriting services or may expect to receive or intend to seek compensation from these companies for the aforesaid services, may have managed or co-managed a public offering, take-over, buyback, delisting offer of securities or various other functions for the companies mentioned in this report.

All rights reserved by the JV. This report or any portion hereof may not be reproduced, distributed or published by any person for any purpose whatsoever. Nor can it be sent to a third party without prior consent of the JV. Action could be taken for unauthorized reproduction, distribution or publication.

Valuation Methodology

To arrive at our 12-months Price Target, the JV uses different valuation methods which include: 1). DCF methodology, 2). Relative valuation methodology, and 3). Asset-based valuation methodology.

Ratings Criteria

JV employs a three-tier ratings system to rate a stock, as mentioned below, which is based upon the level of expected return for a specific stock. The rating is based on the following with time horizon of 12-months.

| Rating | Expected Total Return |
|--------|-------------------------------|
| Buy | Greater than or equal to +15% |
| Hold | Between -5% and +15% |
| Sell | Less than or equal to -5% |

Ratings are updated to account for any development impacting the economy/sector/company, changes in analysts' assumptions or a combination of these factors.

Research Dissemination Policy

The JV endeavours to make all reasonable efforts to disseminate research to all eligible clients in a timely manner through either physical or electronic distribution such as email, fax mail etc.

Analyst Certification

The research analyst, denoted by 'AC' on the cover of this report, has also been involved in the preparation of this report, and is a member of JV's Equity Research Team. The analyst certifies that (1) the views expressed in this report accurately reflect his/her personal views and (2) no part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

Contact Details

Akseer Research (Pvt) Limited

Alpha Capital (Pvt) Limited (Formerly: Alfa Adhi Securities (Pvt) Limited)

1st Floor, Shaheen Chambers, KCHS block 7 & 8, off. Shahrah-e-Faisal 3rd Floor, Shaheen Chambers, KCHS block 7 & 8, off. Shahrah-e-Faisal

T: +92-21-34320359 -60

E: info@akseerresearch.com

T: +92-21-38694242

E: info@alfaadhi.net